Table 1.
Patients’ characteristic
| Parameter | All GBM | mEHT±SAT | Combination treatment | ddTMZ+mEHT | LD-mEHT | HD-mEHT | HD-mEHT <50 years |
|||||||
| (1) | (2) | (3) | (4) | (5) | (6) | (7) | ||||||||
| Value | % | Value | % | Value | % | Value | % | Value | % | Value | % | Value | % | |
| NOP | 76 | 18 | 58 | 54 | 24 | 52 | 23 | |||||||
| Male | 46 | 61% | 10 | 56% | 36 | 62% | 33 | 61% | 16 | 67% | 30 | 58% | 11 | 48% |
| Female | 30 | 39% | 8 | 44% | 22 | 38% | 21 | 39% | 8 | 33% | 22 | 42% | 12 | 52% |
| Earliest born | 24 February 1932 | 24 February 1932 | 19 September 1935 | 19 September 1935 | 24 February 1932 | 18 June 1932 | 31 October 1954 | |||||||
| Latest born | 03 April 1975 | 10 March 1971 | 03 April 1975 | 03 April 1975 | 03 April 1975 | 21 August 1973 | 21 August 1973 | |||||||
| Earliest diagnosed | 01 August 1993 | 01 September 2000 | 01 August 1993 | 01 August 1993 | 12 July 1999 | 01 August 1993 | 01 August 1993 | |||||||
| Latest diagnosed | 15 March 2005 | 03 July 2004 | 15 March 2005 | 30 August 2004 | 08 July 2004 | 15 March 2005 | 15 March 2005 | |||||||
| Age (years) | ||||||||||||||
| Mean | 50.2±1.3 | 55.1±2.8 | 48.7±1.4 | 48.7±1.5 | 50.9±2.6 | 49.9±1.,5 | 39.9±1.2 | |||||||
| Median | 50.4 | 59.1 | 49.8 | 49.8 | 50.8 | 50.2 | 41.0 | |||||||
| Range | 25.9–71.9 | 30.9–71.9 | 25.9–68.2 | 25.9–68.2 | 25.9–68.9 | 27.0–71.9 | 27.0–49.1 | |||||||
| 95% CI | 44.8–53.9 | 44.4–64.9 | 42.7–52.3 | 42.2–52.8 | 42.2–59.8 | 44.4–55.8 | 36.7–43.0 | |||||||
| p Value (t-test) | 0037 | <0.0001* | ||||||||||||
| Elderly (over 68 years) | 4 | 5% | 2 | 11% | 2 | 3% | 2 | 4% | 2 | 8% | 2 | 4% | 0 | 0% |
| Mature (over 50 years) | 40 | 53% | 12 | 67% | 28 | 48% | 26 | 48% | 13 | 54% | 27 | 52% | 0 | 0% |
| Adults (over 20 years) | 76 | 100% | 18 | 100% | 58 | 100% | 54 | 100% | 24 | 100% | 52 | 100% | 23 | 100% |
| Pretreatment: | ||||||||||||||
| Surgery+chemoradiation | 57 | 75% | 13 | 72% | 44 | 76% | 42 | 78% | 15 | 63% | 42 | 81% | 20 | 87% |
| Chemoradiation | 2 | 3% | 1 | 6% | 1 | 2% | 1 | 2% | 1 | 4% | 1 | 2% | 0 | 0% |
| Surgery+radiation | 7 | 9% | 2 | 11% | 5 | 9% | 4 | 7% | 4 | 17% | 3 | 6% | 2 | 9% |
| Surgery+chemotherapy | 5 | 7% | 0 | 0% | 5 | 9% | 4 | 7% | 1 | 4% | 4 | 8% | 1 | 4% |
| Radiaton only | 5 | 7% | 2 | 11% | 3 | 5% | 3 | 6% | 3 | 13% | 2 | 4% | 0 | 0% |
| Chemotherapy total | 64 | 84% | 14 | 78% | 50 | 86% | 47 | 87% | 17 | 71% | 47 | 90% | 21 | 91% |
| Radiation total | 71 | 93% | 18 | 100% | 53 | 91% | 50 | 93% | 23 | 96% | 48 | 92% | 22 | 96% |
| Surgery total | 69 | 91% | 15 | 83% | 54 | 93% | 50 | 93% | 20 | 83% | 49 | 94% | 23 | 100% |
*Versus all GBM sample.
ddTMZ, dose-dense temozolomide; GBM, glioblastoma; HD, high dose; LD, low dose; mEHT, modulated electrohyperthermia; NOP, no. of patients; SAT, supportive and alternative treatments.